FibroBiologics, Inc. (FBLG) stock
FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.83−0.01 (-1.19%)
Close on Nov 19, 2026Market cap $5.53MP/E –Yield –
FibroBiologics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
FibroBiologics's free cash flow for the twelve months ending Jun 30, 2026 was -$14.80M. For fiscal 2025 it was -$16.66M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.66M | – |
| FY2024 | Dec 31, 2024 | -$12.09M | – |
| FY2023 | Dec 31, 2023 | -$6.90M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.29M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.36M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.98M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.20M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.32M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.17M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.01M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.28M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.55M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.65M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.09M | – |
See a number that looks wrong?